| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6888027 | ACROTECH BIOPHARMA | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
Aug, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835501 | ACROTECH BIOPHARMA | Pharmaceutical formulations of HDAC inhibitors |
Oct, 2027
(3 years from now) | |
Beleodaq is owned by Acrotech Biopharma.
Beleodaq contains Belinostat.
Beleodaq has a total of 2 drug patents out of which 0 drug patents have expired.
Beleodaq was authorised for market use on 03 July, 2014.
Beleodaq is available in powder;intravenous dosage forms.
Beleodaq can be used as treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl)..
Drug patent challenges can be filed against Beleodaq from 03 July, 2018.
The generics of Beleodaq are possible to be released after 27 October, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 03, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2019 |
| Orphan Drug Exclusivity(ODE-68) | Jul 03, 2021 |
Drugs and Companies using BELINOSTAT ingredient
NCE-1 date: 03 July, 2018
Market Authorisation Date: 03 July, 2014
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).
Dosage: POWDER;INTRAVENOUS
BELEODAQ family patents
